Plain-English translation of NCT07019220 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a chemotherapy drug that is placed directly into the bladder to treat early-stage bladder cancer. Researchers want to see how well this medication works, how safe it is, and how well patients tolerate it. Unlike surgery to remove tumors, this treatment is delivered through a catheter inserted into the bladder.
Current treatments for low-grade bladder cancer often require surgery or repeated procedures. This trial explores whether this medication, delivered directly to where the cancer is, might offer a less invasive option that could prevent cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You will receive six weekly instillations of the medication directly into your bladder through a catheter—a thin tube inserted through the urethra. Each treatment takes place over six consecutive weeks as an outpatient procedure. Researchers will monitor you closely to check how well the treatment works, track any side effects, and evaluate whether your cancer responds to this approach.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Austria
Phase
Testing effectiveness
Sponsor
Ekaterina Laukhtina
Enrollment target
~47 participants
Started
December 2023
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ekaterina Laukhtina Dr., Medical Doctor
Department of Urology, Medical University of Viernna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.